Table 2 Efficacy and safety data from the three trials comparing rivaroxaban with the European enoxaparin dose as thromboprophylaxis following elective total hip or knee replacement surgery [22–24]
| Â | 10 mg rivaroxaban initiated post-surgery | 40 mg enoxaparin initiated 12 h pre-surgery |
|---|---|---|
RECORD1 trial (hip replacement) | ||
Total VTE and all-cause mortality (primary efficacy end-point) | 18/1595 (1.1%) | 58/1558 (3.7%) |
Major bleeding | 6/2209 (0.3%) | 2/2224 (0.1%) |
RECORD2 trial (hip replacement)* | ||
Total VTE and all-cause mortality (primary efficacy end-point) | 17/864 (2.0%) | 81/869 (9.3%) |
Major bleeding | 1/1228 (0.08%) | 1/1229 (0.08%) |
RECORD3 trial (knee replacement) | ||
Total VTE and all-cause mortality (primary efficacy end-point) | 79/824 (9.6%) | 166/878 (18.9%) |
Major bleeding | 7/1220 (0.6%) | 6/1239 (0.5%) |